Yinjia Biosciences, a Shanghai-based developer of protein reagents and diagnostic products, has reportedly raised close to RMB 100 million (USD 14.76 million) in a Series A financing round. The funding was led by CMB International, with participation from Suzhou Xinhe Guoqing Venture Capital Partnership Ltd. The proceeds will be used to accelerate overseas marketing efforts and enhance global cooperation. Previously, Yinjia Bio closed three financing rounds, raising “hundreds of millions” of renminbi backed by CDH Investments, Gaorong Capital, and Fu Rong Investment.
Product Portfolio and Innovation
Yinjia Bio boasts a portfolio of over 50 high-end proteins, including a calcium-regulated nerve phosphatase (PP2B), adenosyl se, a non-viral carrier specific protein for cell therapy, and a novel antibody for the concomitant diagnosis of liver cancer and gastric cancer. The company’s products cover a wide range of applications, including cell therapies, mRNA vaccines, closed-loop RNA, new drug research and development, and molecular diagnosis and concomitant diagnosis of new tumor drugs.
Future Outlook
The Series A financing round positions Yinjia Biosciences to expand its global footprint and enhance its product offerings. With robust financial backing and a proven track record in innovation, Yinjia Bio is poised to make a significant impact in the biotechnology sector. The company’s focus on overseas marketing and global cooperation underscores its dedication to advancing protein reagents and diagnostic solutions.-Fineline Info & Tech
